The use and abuse of a 4-fold increase in antibody response to assess immunogenicity in early stage vaccine clinical trials
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline Biologicals SA
This publication has 5 references indexed in Scilit:
- A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic CountryFrontiers in Immunology, 2017
- Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in EuropeEBioMedicine, 2017
- Meningococcal surrogates of protection?serum bactericidal antibody activityVaccine, 2005
- Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccinesJournal of Medical Virology, 2005
- Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infectionsJournal of Clinical Microbiology, 1989